Matović, Milovan

Link to this page

Authority KeyName Variants
orcid::0000-0002-2950-2915
  • Matović, Milovan (2)
  • Matović, Milovan D. (2)
Projects

Author's Bibliography

Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera

Vukadinović, Aleksandar; Ravlić, Miroslav; Matović, Milovan; Janković, Drina; Mirković, Marija D.; Radović, Magdalena; Milanović, Zorana; Perić, Marko; Stanković, Dragana; Jevremović, Milutin; Vranješ-Đurić, Sanja

(Beograd : Univerzitet u Beogradu, Institut za nuklearne nauke "Vinča", 2023)

TY  - CONF
AU  - Vukadinović, Aleksandar
AU  - Ravlić, Miroslav
AU  - Matović, Milovan
AU  - Janković, Drina
AU  - Mirković, Marija D.
AU  - Radović, Magdalena
AU  - Milanović, Zorana
AU  - Perić, Marko
AU  - Stanković, Dragana
AU  - Jevremović, Milutin
AU  - Vranješ-Đurić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12187
AB  - Laboratorija za radioizotope Instituta Vinča je jedinstven centar u regionu koji poseduje Rešenja Ministarstva zdravlja Republike Srbije i Direktorata za radijacionu i nuklearnu sigurnost i bezbednost Srbije za proizvodnju radiofarmaceutika. Radiofarmaceutik koji se proizvodi više od 40 godina u Laboratoriji za radioizotope, a primenjuje u terapiji tumora štitaste žlezde, kao i hipertireozi su kapsule natrijum-jodida (I-131). Radijacioni efekti I-131 na ćelije štitaste žlezde potiču od beta-zračenja koje emituje I-131 tokom radioaktivnog raspada u samoj štitastoj žlezdi jer se I-131 nakon oralne primene nakuplja prvenstveno u štitastoj žlezdi u kojoj ima dugu retenciju. Za efikasnu terapiju, ali u isto vreme u cilju smanjenja izloženosti nepotrebnim dozama, za svakog pacijenta određuje se odgovarajuća doza I-131 koju je neophodno da primi, odnosno primenjuje se tzv. personalizovana terapija. U radu je opisan postupak proizvodnje kapsula I-131 u Laboratoriji za radioizotope putem manuelnog punjenja kapsula rastvorom I-131, kao i osnovni zahtevi koje je neophodno da sistem za automatsku proizvodnju radiofarmaceutika ispuni, a to su pre svih, odgovarajuća zaštita operatera od zračenja, jednostavna upotreba i kompjuterska kontrola.
AB  - The Laboratory for radioisotopes of the Vinča Institute is a unique center in the region with licences of the Ministry of Health of the Republic of Serbia and the Directorate for Radiation and Nuclear Safety and Security of Serbia for the production of radiopharmaceuticals. Sodium iodide (I-131) capsules are radiopharmaceuticals that have been produced for more than 40 years in the Laboratory for Radioisotopes, and are used in the treatment of tumors of thyroid gland, as well as in hyperthyroidism. The radiation effects of I-131 on thyroid cells originate from beta-radiation emitted by I-131 during radioactive decay in the thyroid gland itself because I-131 after oral administration accumulates primarily in the thyroid gland where it has a long retention. For the effective therapy, but at the same time in order to reduce exposure to unnecessary high doses, the appropriate dose of I-131 is determined for each patient, in the so-called personalized therapy. The paper describes the current procedure for the production of I-131 capsules in the Laboratory for Radioisotopes by manually filling the capsules with I-131 solution and the basic requirements for design the system for automating the production of radiopharmaceuticals, which above all must provide adequate protection for the operator from radiation, must be user friendly and computer-controlled.
PB  - Beograd : Univerzitet u Beogradu, Institut za nuklearne nauke "Vinča"
PB  - Društvo za zaštitu od zračenja Srbije i Crne Gore
C3  - 32. simpozijum DZZSCG : zbornik radova
T1  - Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera
T1  - Automation of the Production of Radiopharmaceutical with the Aim to Reduce the Operator's Radiation Dose
SP  - 356
EP  - 360
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12187
ER  - 
@conference{
author = "Vukadinović, Aleksandar and Ravlić, Miroslav and Matović, Milovan and Janković, Drina and Mirković, Marija D. and Radović, Magdalena and Milanović, Zorana and Perić, Marko and Stanković, Dragana and Jevremović, Milutin and Vranješ-Đurić, Sanja",
year = "2023",
abstract = "Laboratorija za radioizotope Instituta Vinča je jedinstven centar u regionu koji poseduje Rešenja Ministarstva zdravlja Republike Srbije i Direktorata za radijacionu i nuklearnu sigurnost i bezbednost Srbije za proizvodnju radiofarmaceutika. Radiofarmaceutik koji se proizvodi više od 40 godina u Laboratoriji za radioizotope, a primenjuje u terapiji tumora štitaste žlezde, kao i hipertireozi su kapsule natrijum-jodida (I-131). Radijacioni efekti I-131 na ćelije štitaste žlezde potiču od beta-zračenja koje emituje I-131 tokom radioaktivnog raspada u samoj štitastoj žlezdi jer se I-131 nakon oralne primene nakuplja prvenstveno u štitastoj žlezdi u kojoj ima dugu retenciju. Za efikasnu terapiju, ali u isto vreme u cilju smanjenja izloženosti nepotrebnim dozama, za svakog pacijenta određuje se odgovarajuća doza I-131 koju je neophodno da primi, odnosno primenjuje se tzv. personalizovana terapija. U radu je opisan postupak proizvodnje kapsula I-131 u Laboratoriji za radioizotope putem manuelnog punjenja kapsula rastvorom I-131, kao i osnovni zahtevi koje je neophodno da sistem za automatsku proizvodnju radiofarmaceutika ispuni, a to su pre svih, odgovarajuća zaštita operatera od zračenja, jednostavna upotreba i kompjuterska kontrola., The Laboratory for radioisotopes of the Vinča Institute is a unique center in the region with licences of the Ministry of Health of the Republic of Serbia and the Directorate for Radiation and Nuclear Safety and Security of Serbia for the production of radiopharmaceuticals. Sodium iodide (I-131) capsules are radiopharmaceuticals that have been produced for more than 40 years in the Laboratory for Radioisotopes, and are used in the treatment of tumors of thyroid gland, as well as in hyperthyroidism. The radiation effects of I-131 on thyroid cells originate from beta-radiation emitted by I-131 during radioactive decay in the thyroid gland itself because I-131 after oral administration accumulates primarily in the thyroid gland where it has a long retention. For the effective therapy, but at the same time in order to reduce exposure to unnecessary high doses, the appropriate dose of I-131 is determined for each patient, in the so-called personalized therapy. The paper describes the current procedure for the production of I-131 capsules in the Laboratory for Radioisotopes by manually filling the capsules with I-131 solution and the basic requirements for design the system for automating the production of radiopharmaceuticals, which above all must provide adequate protection for the operator from radiation, must be user friendly and computer-controlled.",
publisher = "Beograd : Univerzitet u Beogradu, Institut za nuklearne nauke "Vinča", Društvo za zaštitu od zračenja Srbije i Crne Gore",
journal = "32. simpozijum DZZSCG : zbornik radova",
title = "Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera, Automation of the Production of Radiopharmaceutical with the Aim to Reduce the Operator's Radiation Dose",
pages = "356-360",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12187"
}
Vukadinović, A., Ravlić, M., Matović, M., Janković, D., Mirković, M. D., Radović, M., Milanović, Z., Perić, M., Stanković, D., Jevremović, M.,& Vranješ-Đurić, S.. (2023). Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera. in 32. simpozijum DZZSCG : zbornik radova
Beograd : Univerzitet u Beogradu, Institut za nuklearne nauke "Vinča"., 356-360.
https://hdl.handle.net/21.15107/rcub_vinar_12187
Vukadinović A, Ravlić M, Matović M, Janković D, Mirković MD, Radović M, Milanović Z, Perić M, Stanković D, Jevremović M, Vranješ-Đurić S. Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera. in 32. simpozijum DZZSCG : zbornik radova. 2023;:356-360.
https://hdl.handle.net/21.15107/rcub_vinar_12187 .
Vukadinović, Aleksandar, Ravlić, Miroslav, Matović, Milovan, Janković, Drina, Mirković, Marija D., Radović, Magdalena, Milanović, Zorana, Perić, Marko, Stanković, Dragana, Jevremović, Milutin, Vranješ-Đurić, Sanja, "Automatizacija procesa proizvodnje radiofarmaceutika u cilju smanjenja doze zračenja operatera" in 32. simpozijum DZZSCG : zbornik radova (2023):356-360,
https://hdl.handle.net/21.15107/rcub_vinar_12187 .

99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent

Mirković, Marija D.; Radović, Magdalena; Stanković, Dragana; Milanović, Zorana; Janković, Drina; Matović, Milovan D.; Jeremić, Marija; Antić, Bratislav; Vranješ-Đurić, Sanja

(2019)

TY  - JOUR
AU  - Mirković, Marija D.
AU  - Radović, Magdalena
AU  - Stanković, Dragana
AU  - Milanović, Zorana
AU  - Janković, Drina
AU  - Matović, Milovan D.
AU  - Jeremić, Marija
AU  - Antić, Bratislav
AU  - Vranješ-Đurić, Sanja
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8156
AB  - Novel theranostic nanoplatform is expected to integrate imaging for guiding and monitoring of the tumor therapy with great therapeutic efficacy and fewer side effects. Here we describe the preparation of a multifunctional 99mTc–bisphosphonate–coated magnetic nanoparticles (MNPs) based on Fe3O4 and coated with two hydrophilic bisphosphonate ligands, i.e., methylene diphosphonate (MDP) and 1–hydroxyethane-1,1- diphosphonate (HEDP). The presence of the bisphosphonates on the MNPs surface, enabled their biocompatibility, colloidal stability and successful binding of the radionuclide. The morphology, size, structure, surface charge and magnetic properties of obtained bisphosphonate–coated Fe3O4 MNPs were characterized by transmission electron microscopy, X–ray powder diffraction, dynamic light scattering, laser Doppler electrophoresis, Fourier transform infrared spectroscopy and vibrating sample magnetometer. The specific power absorption values for Fe3O4–MDP and Fe3O4–HEDP were 113 W/g and 141 W/g, respectively, indicated their heating ability under applied magnetic field. Coated MNPs were radiolabeled with 99mTc using stannous chloride as the reducing agent in a reproducible high yield (95% for Fe3O4–MDP and 97% for Fe3O4–HEDP MNPs) and were remained stable in saline and human serum for 24 h. Ex vivo biodistribution studies presented significant liver and spleen uptake in healthy Wistar rats after intravenous administration at all examined time points due to the colloidal nature of both 99mTc–MNPs. Results of scintigraphy studies are in accordance with ex vivo biodistribution studies, demonstrating high in vivo stability of radiolabeled MNPs and therefore results of both methods were proved as accurate information on the biodistribution profile of investigated MNPs. Overall, in vitro and in vivo stability as well as heating ability, indicate that biocompatible radiolabeled bisphosphonate magnetic nanoparticles exhibit promising potential as a theranostic nanoagent. © 2019 Elsevier B.V.
T2  - Materials Science and Engineering: C
T1  - 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent
VL  - 102
SP  - 124
EP  - 133
DO  - 10.1016/j.msec.2019.04.034
ER  - 
@article{
author = "Mirković, Marija D. and Radović, Magdalena and Stanković, Dragana and Milanović, Zorana and Janković, Drina and Matović, Milovan D. and Jeremić, Marija and Antić, Bratislav and Vranješ-Đurić, Sanja",
year = "2019",
abstract = "Novel theranostic nanoplatform is expected to integrate imaging for guiding and monitoring of the tumor therapy with great therapeutic efficacy and fewer side effects. Here we describe the preparation of a multifunctional 99mTc–bisphosphonate–coated magnetic nanoparticles (MNPs) based on Fe3O4 and coated with two hydrophilic bisphosphonate ligands, i.e., methylene diphosphonate (MDP) and 1–hydroxyethane-1,1- diphosphonate (HEDP). The presence of the bisphosphonates on the MNPs surface, enabled their biocompatibility, colloidal stability and successful binding of the radionuclide. The morphology, size, structure, surface charge and magnetic properties of obtained bisphosphonate–coated Fe3O4 MNPs were characterized by transmission electron microscopy, X–ray powder diffraction, dynamic light scattering, laser Doppler electrophoresis, Fourier transform infrared spectroscopy and vibrating sample magnetometer. The specific power absorption values for Fe3O4–MDP and Fe3O4–HEDP were 113 W/g and 141 W/g, respectively, indicated their heating ability under applied magnetic field. Coated MNPs were radiolabeled with 99mTc using stannous chloride as the reducing agent in a reproducible high yield (95% for Fe3O4–MDP and 97% for Fe3O4–HEDP MNPs) and were remained stable in saline and human serum for 24 h. Ex vivo biodistribution studies presented significant liver and spleen uptake in healthy Wistar rats after intravenous administration at all examined time points due to the colloidal nature of both 99mTc–MNPs. Results of scintigraphy studies are in accordance with ex vivo biodistribution studies, demonstrating high in vivo stability of radiolabeled MNPs and therefore results of both methods were proved as accurate information on the biodistribution profile of investigated MNPs. Overall, in vitro and in vivo stability as well as heating ability, indicate that biocompatible radiolabeled bisphosphonate magnetic nanoparticles exhibit promising potential as a theranostic nanoagent. © 2019 Elsevier B.V.",
journal = "Materials Science and Engineering: C",
title = "99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent",
volume = "102",
pages = "124-133",
doi = "10.1016/j.msec.2019.04.034"
}
Mirković, M. D., Radović, M., Stanković, D., Milanović, Z., Janković, D., Matović, M. D., Jeremić, M., Antić, B.,& Vranješ-Đurić, S.. (2019). 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent. in Materials Science and Engineering: C, 102, 124-133.
https://doi.org/10.1016/j.msec.2019.04.034
Mirković MD, Radović M, Stanković D, Milanović Z, Janković D, Matović MD, Jeremić M, Antić B, Vranješ-Đurić S. 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent. in Materials Science and Engineering: C. 2019;102:124-133.
doi:10.1016/j.msec.2019.04.034 .
Mirković, Marija D., Radović, Magdalena, Stanković, Dragana, Milanović, Zorana, Janković, Drina, Matović, Milovan D., Jeremić, Marija, Antić, Bratislav, Vranješ-Đurić, Sanja, "99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent" in Materials Science and Engineering: C, 102 (2019):124-133,
https://doi.org/10.1016/j.msec.2019.04.034 . .
29
15
26

Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation

Spasojević-Tišma, Vera D.; Matović, Milovan; Mihaljević, Olgica B.; Živančević-Simonović, Snežana T.; Jeremic, Marija Z.; Jakovljević, Vladimir Lj.; Todorović, Vera N.; Pavlović, Ivan; Pejić, Snežana; Todorović, Ana

(2017)

TY  - JOUR
AU  - Spasojević-Tišma, Vera D.
AU  - Matović, Milovan
AU  - Mihaljević, Olgica B.
AU  - Živančević-Simonović, Snežana T.
AU  - Jeremic, Marija Z.
AU  - Jakovljević, Vladimir Lj.
AU  - Todorović, Vera N.
AU  - Pavlović, Ivan
AU  - Pejić, Snežana
AU  - Todorović, Ana
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1935
AB  - The radioactive iodine (I-131) ablation is a well-accepted treatment modality for differentiated thyroid cancer patients. Unfortunately, the radiation induces the oxidative stress and damages cells and tissues, simultaneously activating the mechanisms of antioxidative defense. Since the mechanisms of those processes are not completely known, we wanted to examine the changes in the most important reactive oxygen species and antioxidative components, as well as their correlation and significance for lipid peroxidation. Our results showed that the level of thiobarbituric acid reactive substances was increased during the first 30 days after the radiotherapy. Among antioxidant components, superoxide dismutase was increased in the 3rd and 30th day; catalase in 7th and reduced glutathione in 3rd and 7th day after the radiotherapy. As regards the prooxidants, the reduction of hydrogen peroxide (H2O2) was recorded in 7th and 30th day, and superoxide anion radical (O-2(center dot-)) was unchanged after the exposure to I-131. These results indicate that differentiated thyroid cancer patients are under constant oxidative stress despite the observed increase in antioxidative and reduction in prooxidative parameters. The understanding of these early processes is important since their progress determines the latter effects of I-131 therapy.
T2  - Nuclear technology and radiation protection
T1  - Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation
VL  - 32
IS  - 4
SP  - 358
EP  - 365
DO  - 10.2298/NTRP1704358S
ER  - 
@article{
author = "Spasojević-Tišma, Vera D. and Matović, Milovan and Mihaljević, Olgica B. and Živančević-Simonović, Snežana T. and Jeremic, Marija Z. and Jakovljević, Vladimir Lj. and Todorović, Vera N. and Pavlović, Ivan and Pejić, Snežana and Todorović, Ana",
year = "2017",
abstract = "The radioactive iodine (I-131) ablation is a well-accepted treatment modality for differentiated thyroid cancer patients. Unfortunately, the radiation induces the oxidative stress and damages cells and tissues, simultaneously activating the mechanisms of antioxidative defense. Since the mechanisms of those processes are not completely known, we wanted to examine the changes in the most important reactive oxygen species and antioxidative components, as well as their correlation and significance for lipid peroxidation. Our results showed that the level of thiobarbituric acid reactive substances was increased during the first 30 days after the radiotherapy. Among antioxidant components, superoxide dismutase was increased in the 3rd and 30th day; catalase in 7th and reduced glutathione in 3rd and 7th day after the radiotherapy. As regards the prooxidants, the reduction of hydrogen peroxide (H2O2) was recorded in 7th and 30th day, and superoxide anion radical (O-2(center dot-)) was unchanged after the exposure to I-131. These results indicate that differentiated thyroid cancer patients are under constant oxidative stress despite the observed increase in antioxidative and reduction in prooxidative parameters. The understanding of these early processes is important since their progress determines the latter effects of I-131 therapy.",
journal = "Nuclear technology and radiation protection",
title = "Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation",
volume = "32",
number = "4",
pages = "358-365",
doi = "10.2298/NTRP1704358S"
}
Spasojević-Tišma, V. D., Matović, M., Mihaljević, O. B., Živančević-Simonović, S. T., Jeremic, M. Z., Jakovljević, V. Lj., Todorović, V. N., Pavlović, I., Pejić, S.,& Todorović, A.. (2017). Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation. in Nuclear technology and radiation protection, 32(4), 358-365.
https://doi.org/10.2298/NTRP1704358S
Spasojević-Tišma VD, Matović M, Mihaljević OB, Živančević-Simonović ST, Jeremic MZ, Jakovljević VL, Todorović VN, Pavlović I, Pejić S, Todorović A. Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation. in Nuclear technology and radiation protection. 2017;32(4):358-365.
doi:10.2298/NTRP1704358S .
Spasojević-Tišma, Vera D., Matović, Milovan, Mihaljević, Olgica B., Živančević-Simonović, Snežana T., Jeremic, Marija Z., Jakovljević, Vladimir Lj., Todorović, Vera N., Pavlović, Ivan, Pejić, Snežana, Todorović, Ana, "Redox Parameters in Blood of Thyroid Cancer Patients After the Radioiodine Ablation" in Nuclear technology and radiation protection, 32, no. 4 (2017):358-365,
https://doi.org/10.2298/NTRP1704358S . .
1
1
1

Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију

Jeremić, Marija Ž.; Matović, Milovan D.; Krstić, Dragana Ž.; Nikezić, Dragoslav

(Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе, 2017)

TY  - CONF
AU  - Jeremić, Marija Ž.
AU  - Matović, Milovan D.
AU  - Krstić, Dragana Ž.
AU  - Nikezić, Dragoslav
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8294
UR  - https://plus.sr.cobiss.net/opac7/bib/245691404
UR  - http://dzz.org.rs/wp-content/uploads/2013/06/Zbornik_XXIX_Simpozijum_DZZ_SCG_Srebrno_jezero_2.pdf
AB  - У овом раду одређени су коефицијенти трансфера у биокинетичком моделу за
90Y-DOTATOC неуроендокриних тумора. Неуроендокрини тумори (NETs) су
малигни тумори који најчешће захватају органе гастроинтестиналног тракта и
панкреас (GEP-NETs), мада се могу јавити и на другим ткивима, као што су
плућа и ређе на дојкама, тимусу и урогениталном систему. Када су ови тумори
добро диферентовани, терапија избора је пептидна радионуклидна терапија
(PRRT), која се базира на аналозима соматостатина обележеним снажним бета
емитером, као што је 90Y, чији је максимални домет у меким ткивима 11,3 mm,
што омогућава да се са великом вероватноћом уништи велики део туморског
ткива и заустави прогресија малигне болести.
Циљ овог рада је да се на основу доступних метода мерења дистрибуције
90Y-DOTATOC у органима људског тела и на основу решења математичког
модела одреде трансфер коефицијенти за критичне органе, као и за тумор, а на
основу којих је касније могуће извршити прорачун апсорбованих доза у тим
органима и туморском ткиву.
AB  - Transfer coefficients in biokinetic model for 90Y-DOTATOC therapy of
neuroendocrinetumour (NETs) were determined in this work. These tumours are usually
treatted by DOTATOC therapy where some peptide was labeled with 90Y, which is a
strong beta emiter. The range of beta particles in soft tissues is less than 11.3 mm which
enables destroying of tumour cells with large probabiliy. The objective of this work was
to develop biokinetic model for 90Y-DOTATOC and to analytically solve obtained
equations. As a result of this model, the system with 10 equaitions and 12 unknown
constants was obtained. Two additional equations sjould be found: first one was
obtained from the normalisation of system and the second one from measurements.
PB  - Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе
C3  - 29. симпозијум ДЗЗСЦГ : зборник радова
T1  - Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију
T1  - Determination of transfer coefficients in biokinetic model for Y-90-DOTATOC therapy
SP  - 320
EP  - 327
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8294
ER  - 
@conference{
author = "Jeremić, Marija Ž. and Matović, Milovan D. and Krstić, Dragana Ž. and Nikezić, Dragoslav",
year = "2017",
abstract = "У овом раду одређени су коефицијенти трансфера у биокинетичком моделу за
90Y-DOTATOC неуроендокриних тумора. Неуроендокрини тумори (NETs) су
малигни тумори који најчешће захватају органе гастроинтестиналног тракта и
панкреас (GEP-NETs), мада се могу јавити и на другим ткивима, као што су
плућа и ређе на дојкама, тимусу и урогениталном систему. Када су ови тумори
добро диферентовани, терапија избора је пептидна радионуклидна терапија
(PRRT), која се базира на аналозима соматостатина обележеним снажним бета
емитером, као што је 90Y, чији је максимални домет у меким ткивима 11,3 mm,
што омогућава да се са великом вероватноћом уништи велики део туморског
ткива и заустави прогресија малигне болести.
Циљ овог рада је да се на основу доступних метода мерења дистрибуције
90Y-DOTATOC у органима људског тела и на основу решења математичког
модела одреде трансфер коефицијенти за критичне органе, као и за тумор, а на
основу којих је касније могуће извршити прорачун апсорбованих доза у тим
органима и туморском ткиву., Transfer coefficients in biokinetic model for 90Y-DOTATOC therapy of
neuroendocrinetumour (NETs) were determined in this work. These tumours are usually
treatted by DOTATOC therapy where some peptide was labeled with 90Y, which is a
strong beta emiter. The range of beta particles in soft tissues is less than 11.3 mm which
enables destroying of tumour cells with large probabiliy. The objective of this work was
to develop biokinetic model for 90Y-DOTATOC and to analytically solve obtained
equations. As a result of this model, the system with 10 equaitions and 12 unknown
constants was obtained. Two additional equations sjould be found: first one was
obtained from the normalisation of system and the second one from measurements.",
publisher = "Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе",
journal = "29. симпозијум ДЗЗСЦГ : зборник радова",
title = "Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију, Determination of transfer coefficients in biokinetic model for Y-90-DOTATOC therapy",
pages = "320-327",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8294"
}
Jeremić, M. Ž., Matović, M. D., Krstić, D. Ž.,& Nikezić, D.. (2017). Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију. in 29. симпозијум ДЗЗСЦГ : зборник радова
Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе., 320-327.
https://hdl.handle.net/21.15107/rcub_vinar_8294
Jeremić MŽ, Matović MD, Krstić DŽ, Nikezić D. Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију. in 29. симпозијум ДЗЗСЦГ : зборник радова. 2017;:320-327.
https://hdl.handle.net/21.15107/rcub_vinar_8294 .
Jeremić, Marija Ž., Matović, Milovan D., Krstić, Dragana Ž., Nikezić, Dragoslav, "Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију" in 29. симпозијум ДЗЗСЦГ : зборник радова (2017):320-327,
https://hdl.handle.net/21.15107/rcub_vinar_8294 .